ReviewInternational journal of molecular sciences2021
Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 3 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Hepatoprotective effects of oyster-derived bioactive compounds in alcoholic liver disease: a systematic review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Pooled it
- Prognostic biomarkers for predicting decompensation in alcoholic and non-alcoholic patients with compensated cirrhosis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2022Pooled it
- Ya-Jie-Sha-Ba Decoction Regulates Arachidonic Acid Metabolism to Treat Alcohol-Associated Liver Disease by Activating PPARα-CYP4A14 Axis: Insights From Multi-Omics Analysis and Experimental Validations.Journal of cellular and molecular medicine · 2026Article
- Article
- Liver Dysfunction Explains a Substantial Proportion of Circulating cfDNA Variability in HCC: An Exploratory Study.Biomedicines · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol-related liver disease in human immunodeficiency virus.World journal of virology · 2026Review
- Alcohol consumption and cancer progression: Mechanistic insights, immune dysregulation, and public health implications.Translational oncology · 2026Review
- Innovative analysis and future prospects of Bupleuri Radix's pharmacology and toxicity based on the gut-liver axis.MedScience · 2026Review
- Chronic hepatitis B virus infection and the risk of extrahepatic malignancies: an updated review of epidemiology, mechanisms, and clinical implications.Virology journal · 2026Review
- Risk factors for significant hepatic fibrosis in alcoholic liver disease and construction of a nomogram prediction model.BMC gastroenterology · 2026Article
- Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation.Hepatology communications · 2026Article
- Causal Relationship Between 38 Dietary Factors, Including Sugar and Alcohol Intakes, and Polycystic Ovary Syndrome: A Two-Sample Mendelian Randomization Study.International journal of women's health · 2026Article
- Knowledge, attitude, and practice towards fatty liver disease among the general population in Shanghai, China: a community-based cross-sectional study.Frontiers in public health · 2026Article
- Trajectories of symptom burden and associated factors in patients with liver cirrhosis: a prospective study.Frontiers in medicine · 2026Article
- Therapeutic Potential of Silver Nanoparticles in Hepatocellular Carcinoma: From Pathogenesis to Clinical Perspectives.International journal of nanomedicine · 2026Review
- Global Trends in Hepatocellular Carcinoma and TGF-β Research: A Bibliometric and Visualization Analysis from 2000 to 2024.Current protein & peptide science · 2026Article
- Zonation, Zonation, Zonation: The Real Estate of the Liver.Annual review of pathology · 2026Review
- Dicaffeoylquinic acid alleviates alcoholic liver disease by targeting PLA2G4B and inhibiting the MAPK signaling pathway.Frontiers in pharmacology · 2026Article
- Synergistic toxicity in alcohol-associated liver disease and PFAS exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2025Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol-related liver disease (ALD) refers to the liver damage occurring due to excessive alcohol consumption and involves a broad spectrum of diseases that includes liver steatosis, steatohepatitis, hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The progression of ALD is mainly associated with the amount and duration of alcohol usage; however, it is also influenced by genetic, epigenetic, and environmental factors. The definite diagnosis of ALD is based on a liver biopsy, although several non-invasive diagnostic tools and serum biomarkers have emerging roles in the early detection of ALD. While alcohol abstinence and nutritional support remain the cornerstone of ALD treatment, growing evidence has revealed that the therapeutic agents that target oxidative stress or gut-liver axis, inflammatory response inhibition, and liver regeneration enhancement also play a role in ALD management. Furthermore, microRNAs modulation and mesenchymal stem cell-based therapy have emerging potential as ALD therapeutic options. This review summarizes the updated understanding of the pathophysiology, diagnosis, and novel therapeutic approaches for ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.